The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Leather Services Business Unit of Clariant International Ltd
Advised Clariant International Ltd, the Swiss specialty chemicals company, on the sale of its Leather Services Business Unit to Stahl Holdings (portfolio company of Wendel), a leading supplier in the leather chemicals and performance coating industries
Detergents & Intermediates Business Unit of Clariant International Ltd
Advised Clariant International Ltd, the Swiss specialty chemicals company, on the sale of its Detergents & Intermediates Business Unit to International Chemical Investors Group, a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses
Aztec (subsidiary of Dentsu Inc.)
Advised Dentsu Inc., Asia’s largest advertising agency, on the sale of its retail data analytics subsidiary Aztec, to IRI, a global market research company
Schenck Process Holding GmbH
Advised Schenck Process Holding GmbH, a global leader in bulk material handling, providing applications incorporating weighing, feeding, screening and automation solutions, on the establishment and implementation of a refinancing solution leading to the amendment and extension of its existing senior and mezzanine syndicated facilities
Warner Chilcott, plc
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
Azelis S.A.
Advised Azelis S.A., a Pan-European distributor of specialty chemicals owned by funds managed by 3i plc, on its covenant reset and a two year maturity extension of its €240mm syndicated debt package
Champion Flour Limited
Advised Goodman Fielder, a leading Australian listed food company, on the sale of its New Zealand flour milling business, Champion Flour, to Nisshin Seifun Group Inc.
SAS Group
Advised the Norwegian Government in relation to some specific issues in connection with the restructuring of SAS, the leading airline group in Northern Europe
Becker Underwood
Advised Norwest Equity Partners on the sale of its portfolio company Becker Underwood, a global leader in the development and commercialization of yield-improving seed-applied biological products for the Agricultural market, to BASF, the world’s largest chemical company
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
Aegis Group plc
Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia
Village Roadshow Entertainment Group
Advised Village Roadshow Entertainment Group on its $275 million mezzanine and equity capital raise from a group of investors
Minority stake in Stadler Rail
Advised Capvis, one of the leading buyout firms in Switzerland and one of the main mid-market private equity firms in German-speaking Europe, on the staged exit from of its 20% minority stake in Stadler Rail, by selling to Peter Spuhler, CEO and majority shareholder in Stadler Rail
MSF Sugar
Advised MSF Sugar, Australia’s third largest producer and second largest exporter of sugar, on an acquisition proposal from Mitr Phol Sugar Corp. of Thailand at an offer value of ~31% premium to previous close
The Synovate Group
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
KemFine Group Oy
Advised 3i on the disposal of KemFine Group Oy, a leading custom manufacturer of fine chemicals, to CABB AG
Citigroup (selected private equity assets)
Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup
Close Brothers Cayman Limited
Advised Close Brothers plc, an independent financial services group, on the sale of its Cayman based offshore business to Intertrust Group Holdings SA
CABB GmbH
Advised Bridgepoint Advisors Limited on the acquisition of CABB GmbH, a German global provider of fine and specialty chemicals and custom manufacturing solutions
Troika Dialog Group Limited
Advised TD Advisors Limited, a major shareholder of Troika Dialog Group, Russia’s leading investment bank, on the sale of their stake as part of the acquisition of Troika Dialog Group by Sberbank, the largest commercial bank in Russia
Tyndall Investments
Advised Suncorp, on the sale of its investment management business, Tyndall Investments, in Australia and New Zealand to Nikko Asset Management, a leading Asian mutual funds management company
telerob Holding GmbH
Advised the shareholders of telerob Holding GmbH, a German-based market leader in the development and manufacture of advanced bomb disposal robots and integrated threat response vehicles, on the sale of the Company to Cobham plc, the UK-based, internationally operating aerospace, defence and security technology group
TOWER Australia Group Limited
Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement
Alcon, Inc.
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company